TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
One Percent Rule Checklist For Safer Forex Trading Risk 
MENLO PARK, Calif., April 06, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day.
Event: Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day
Date: April 27, 2017
Time: 5:00 pm EDT
Location: Boston, MA
A live and replay video webcast of the presentation will be available at http://www.arminvestorday.com/webcast.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Jill Steier Senior Vice President The Trout Group LLC 646-378-2946 [email protected]
